Profund Advisors LLC Neurocrine Biosciences Inc Transaction History

Profund Advisors LLC

$2.59 Billion
Q3 2024

A detailed history of Profund Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Profund Advisors LLC holds 29,108 shares of NBIX stock, worth $4.27 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

29,108

Previous 24,317 19.7%

Holding current value

$4.27 Million

Previous $3.35 Million 0.12%

% of portfolio

0.13%

Previous 0.13%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $548,952 - $733,741	4,791 Added 19.7%	29,108 $3.35 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $1.36 Million - $1.49 Million	10,405 Added 74.79%	24,317 $3.35 Million
Q1 2024 May 08, 2024	SELL	$130.4 - $143.74 $177,213 - $195,342	-1,359 Reduced 8.9%	13,912 $1.92 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $78,067 - $97,711	-736 Reduced 4.6%	15,271 $2.01 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $267,674 - $333,383	-2,847 Reduced 15.1%	16,007 $1.8 Million
Q2 2023 Aug 10, 2023	BUY	$89.53 - $104.87 $236,001 - $276,437	2,636 Added 16.25%	18,854 $1.78 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $219,276 - $286,636	2,330 Added 16.78%	16,218 $1.64 Million
Q4 2022 Feb 02, 2023	BUY	$106.72 - $127.06 $32,549 - $38,753	305 Added 2.25%	13,888 $1.66 Million
Q3 2022 Nov 04, 2022	SELL	$92.03 - $107.81 $47,119 - $55,198	-512 Reduced 3.63%	13,583 $1.44 Million
Q2 2022 Aug 01, 2022	SELL	$75.79 - $100.07 $112,396 - $148,403	-1,483 Reduced 9.52%	14,095 $1.37 Million
Q1 2022 May 10, 2022	SELL	$72.45 - $94.81 $122,875 - $160,797	-1,696 Reduced 9.82%	15,578 $1.46 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $209,957 - $279,995	-2,636 Reduced 13.24%	17,274 $1.47 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $106,259 - $122,103	-1,233 Reduced 5.83%	19,910 $1.91 Million
Q2 2021 Aug 12, 2021	SELL	$89.43 - $102.27 $39,080 - $44,691	-437 Reduced 2.03%	21,143 $2.06 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $222,427 - $303,276	2,540 Added 13.34%	21,580 $2.1 Million
Q4 2020 Feb 09, 2021	BUY	$86.91 - $108.33 $148,442 - $185,027	1,708 Added 9.85%	19,040 $1.83 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $312,231 - $438,832	-3,247 Reduced 15.78%	17,332 $1.67 Million
Q2 2020 Aug 03, 2020	BUY	$85.09 - $130.36 $278,584 - $426,798	3,274 Added 18.92%	20,579 $2.51 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $474,094 - $718,053	-6,312 Reduced 26.73%	17,305 $1.5 Million
Q4 2019 Feb 18, 2020	BUY	$86.8 - $118.57 $220,558 - $301,286	2,541 Added 12.06%	23,617 $2.54 Million
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $118,437 - $143,419	-1,413 Reduced 6.28%	21,076 $1.9 Million
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $203,427 - $257,016	-2,816 Reduced 11.13%	22,489 $1.9 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $26,822 - $35,422	387 Added 1.55%	25,305 $2.23 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $410,671 - $747,527	-6,011 Reduced 19.43%	24,918 $1.78 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $298,419 - $379,815	3,018 Added 10.81%	30,929 $3.8 Million
Q2 2018 Aug 13, 2018	SELL	$75.3 - $105.99 $105,344 - $148,280	-1,399 Reduced 4.77%	27,911 $2.74 Million
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $235,531 - $286,902	-3,104 Reduced 9.58%	29,310 $2.43 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $238,626 - $316,334	-4,077 Reduced 11.17%	32,414 $2.52 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $138,585 - $177,037	2,889 Added 8.6%	36,491 $2.24 Million
Q2 2017 Aug 11, 2017	BUY	N/A	33,602	33,602 $1.55 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

93.9M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Neurocrine Biosciences Inc Transaction History